direct reprogramming factors
From iPSC to induced beta-cells, iN and iCM: dedifferentiation vs direct reprogramming
The success of inducing pluripotency in primary fibroblasts and other cells with a combination of only a small number of transcription factors suggested that fully differentiated cells might change fate following similar treatments. Since the demonstration of induced pluripotent stem cells (iPSCs), at least three examples have been published where 3 cell type-specific factors were selected from a pool of 10-20 candidates that, when expressed from viral vectors, could induce beta-cells, neurons, or cardiomyocytes.
Induced beta-cells [1]: Ngn3, Pdx1, and Mafa, adenovirus injected to in vivo targets
Induced neurons (iN) [2]: Ascl1, Brn2, and Myt1l, lentivirus infecting mouse embryonic fibroblasts (MEF) or tail tip fibroblasts (TTF)
Induced cardiomyocytes (iCM) [3]: Gata4, Mef2c, and Tbx5, lentivirus infecting cardiac fibroblasts or TTF
In all 3 cases, the change of fate seemed to be via direct conversion, without passing through a progenitor cell fate before further differentiation. Like iPSC reprogramming, direct reprogramming also requires a transient supply of inducing factors. Unlike generating iPSCs, the percentage of cells getting reprogrammed is much higher in direct reprogramming, ~20% in the cases of iN and iCM vs 0.1-1% in iPSC. It is likely that a transient, inductive expression of essential factors jump-starts endogenous factors to establish cell fate specific programs; it has also been illustrated that chromatin remodeling through DNA methylation, histone modifications, etc. accompanies the direct reprogramming events.
The requirement of the full complement of inducting factors may vary depending on how close the original cell type is to the new cell type. iPSCs are typically created by using 4 genes, but can be created with just Sox2, Oct3/4 particularly when the cells to be reprogrammed are less differentiated, such as tissue progenitor cells. Instead of a more “complete” direct reprogramming from unrelated cells to iN and iCM, the induced beta-cells come from exocrine cells, which share parental cells with beta-cells.
Looking into the near future, it should be expected that cell type-specific gene expression profiles are being re-examined or created right this moment to look for candidate gene pools specific to other cell types, starting from those with cell therapy relevance. Lentivirus, retrovirus, adenovirus, or baculovirus for mammalian expression are being constructed to carry them into fibroblasts or cells that are close to the end product of direct reprogramming. In a few months, many of these inducing gene-expressing viruses will become shelf products as high titer viruses from suppliers like Allele Biotech, incorporating tools in viral packaging, fluorescent proteins, and polycistronic gene expression systems.
- New Product of the Week 081610-082210:
96 Genomic DNA Isolation Mini Kit (Tissues/Cells), ABP-PP-JG090S $229.00, the best solution for for high through-put DNA isolation, first of a brand new product series offered from Allele.
- Promotion of the Week 081610-082210:
last call for half price Premium Agarose for DNA or RNA gel. Place order today and secure the low price.
1. Zhou, Q., J. Brown, A. Kanarek, J. Rajagopal, and D.A. Melton, In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature, 2008. 455(7213): p. 627-32.
2. Vierbuchen, T., A. Ostermeier, Z.P. Pang, Y. Kokubu, T.C. Sudhof, and M. Wernig, Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 463(7284): p. 1035-41.
3. Ieda, M., J.D. Fu, P. Delgado-Olguin, V. Vedantham, Y. Hayashi, B.G. Bruneau, and D. Srivastava, Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 142(3): p. 375-86.
Categories
- Allele Mail Bag
- cGMP
- Customer Feedback
- Fluorescent proteins
- iPSCs and other stem cells
- nAb: Camelid Antibodies, Nanobodies, VHH
- Next Generation Sequencing (NextGen Seq)
- NIH Budget and You
- oligos and cloning
- Open Forum
- RNAi patent landscape
- SBIR and Business issues
- State of Research
- Synthetic biology
- Uncategorized
- Viruses and cells
- You have the power
Archives
- October 2018
- April 2018
- March 2018
- January 2018
- October 2017
- September 2017
- August 2017
- March 2017
- February 2017
- January 2017
- November 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- February 2016
- October 2015
- September 2015
- August 2015
- June 2015
- March 2015
- January 2015
- December 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- May 2012
- April 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- October 2008
- August 2008
- July 2008